|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
increases incretin levels
increases insulin sensitivity
decreases hepatic glucose production
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Janumet_XR
|
|
gptkbp:class
|
biguanide and DPP-4 inhibitor
|
|
gptkbp:clinical_trial
|
ongoing research
|
|
gptkbp:contains
|
gptkb:sitagliptin
gptkb:metformin
|
|
gptkbp:contraindication
|
renal impairment
hypersensitivity to components
|
|
gptkbp:dosage_form
|
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janumet XR
|
|
gptkbp:interacts_with
|
gptkb:Company
other antidiabetic agents
|
|
gptkbp:is_available_in
|
various strengths
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
|
|
gptkbp:previous_name
|
metformin/sitagliptin
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:scholarships
|
monitor blood sugar levels
exercise regularly
maintain a balanced diet
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
|
|
gptkbp:storage
|
store at room temperature
keep away from moisture
|
|
gptkbp:bfsParent
|
gptkb:Janumet
|
|
gptkbp:bfsLayer
|
6
|